Concomitant Coronary Artery Disease and Lung Cancer

  • Wilhelm P. MistiaenEmail author


It is common for patients presenting with a newly diagnosed lung mass to have concomitant coronary artery disease. The Society of Thoracic Surgeons database reports a 20.9% incidence rate of coronary artery disease in patients undergoing pulmonary resection for primary lung cancer. These two conditions have multiple coinciding risk factors, including increased age, tobacco use, and lifestyle. As a result, a high overlap of patients with concomitant disease is expected. This cohort of patients presents a significant challenge for decision-making and therapeutic intervention as there is no consensus on how to best treat this patient population. This chapter attempts to address issues such as the choice between a one- or two-stage procedure, the use of extracorporeal circulation for myocardial revascularization, the choice of incision and the extent of pulmonary resection.


Coronary artery disease Lung cancer Lung resection Off-pump coronary artery bypass grafting Surgery 


  1. 1.
    Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016;4:256–67.CrossRefGoogle Scholar
  2. 2.
  3. 3.
    Waller D. Thoracic intervention & surgery to cure lung cancer: margin not lobe is the new gold standard. J R Soc Med. 2018;2018:141076818775078.Google Scholar
  4. 4.
    Kauffmann M, Krüger T, Aebert H. Surgery on extracorporeal circulation in early and advanced non-small cell lung cancer. Thorac Cardiovasc Surg. 2013;61:103–8.CrossRefGoogle Scholar
  5. 5.
    Ma X, Huang F, Zhang Z, Song F, Ou S. Lung cancer resection with concurrent off-pump coronary artery bypasses: safety and efficiency. J Thorac Dis. 2016;8:2038–45.CrossRefGoogle Scholar
  6. 6.
    Cathenis K, Hamerlijnck R, Vermassen F, Van Nooten G, Muysoms F. Concomitant cardiac surgery and pulmonary resection. Acta Chir Belg. 2009;109:306–11.CrossRefGoogle Scholar
  7. 7.
    Zhang H, Wang D, Xiao F, et al. The impact of previous or concomitant myocardium revascularization on the outcomes of patients undergoing major non-cardiac surgery. Interact Cardiovasc Thorac Surg. 2009;9:788–92.CrossRefGoogle Scholar
  8. 8.
    Voets AJ, Sheik Joesoef KS, Van Teeffelen ME. The influence of open-heart surgery on survival of patients with co-existent surgically amenable lung cancer (stage I and II). Eur J Cardiothorac Surg. 1997;12:898–902.CrossRefGoogle Scholar
  9. 9.
    Johnson JA, Landreneau RJ, Boley TM, et al. Should pulmonary lesions be resected at the time of open heart surgery? Am Surg. 1996;62:300–3.PubMedGoogle Scholar
  10. 10.
    Kanzaki R, Kimura T, Kawamura T, Funaki S, Shintani Y, Mimani M, Miyagawa S, Toda K, Swa Y, Okumura M. Treatment of simultaneously discovered lung cancer and cardiovascular disease: a 20-year single-institution experience. Surg Today. 2017;43:726–32.CrossRefGoogle Scholar
  11. 11.
    Darwazah AK, Osman M, Sharabati B. Use of off-pump coronary artery bypass surgery among patients with malignant disease. J Card Surg. 2010;25:1–4.CrossRefGoogle Scholar
  12. 12.
    Suzuki S, Usui A, Yoshida K, et al. Effect of cardiopulmonary bypass on cancer prognosis. Asian Cardiovasc Thorac Ann. 2010;18:536–40.CrossRefGoogle Scholar
  13. 13.
    Fu Q, Li QZ, Liang D, Ruan XH, Wang ZX, Wei MX. Early and long-term results of combined cardiac surgery and neoplastic resection in patients with concomitant severe heart disease and neoplasms. Chin Med J (Engl). 2011;124:1939–42.Google Scholar
  14. 14.
    Santavy P, Szkorupa M, Bohanes T, Lonsky V. Simultaneous cardiac surgery with pulmonary resection. Cor Vasa. 2015;57:e82–5.CrossRefGoogle Scholar
  15. 15.
    Yang Y, Xiao F, Wang J, Song B, Li XH, Li J, He ZS, Zhang H, Yin L. Simultaneous surgery in patients with both cardiac and noncardiac disease. Patient Prefer Adherence. 2016;10:1251–8.CrossRefGoogle Scholar
  16. 16.
    Kaku R, Teramoto K, Ishida K, Igashari T, Hashimoto M, Kitamura S, Tezuka N, Asai T, Hanaoka J. Simultaneous resection of pulmonary tumor following cardiovascular surgery. Asian J Surg. 2017;40:12–128.CrossRefGoogle Scholar
  17. 17.
    Maeda H, Kanzaki M, Sakamoto K, Isaka T, Yamazaki K, Onuki T. Surgery for non-smalle cell lung cancer in patients with a history of cardiovascular surgery. Surg Today. 2017;47:284–92.CrossRefGoogle Scholar
  18. 18.
    Sandri A, Petersen RH, Decaluwe H, Moons J, Ferguson MK, Hansen HJ, Brunelli A. Coronary artery disease is associated with an increased mortality rate following video assisted thoracoscopic lobectomy. J Thorac Cardiovasc Surg. 2017;154(1):352–7.CrossRefGoogle Scholar
  19. 19.
    Wei B, Broussard B, Bryant A, Linsky P, Minnich DJ, Cerfolio RJ. Left upper lobectomy after coronary bypass grafting. J Thorac Cardiovasc Surg. 2015;150:531–5.CrossRefGoogle Scholar
  20. 20.
    Shah AA, Worni M, Onaitis MW, Balderson SS, Harpole DH, D’Amico TA, Berry MF. Thoracoscopic left upper lobectomy in patients with internal mammary artery coronary bypass grafts. Ann Thorac Surg. 2014;98:1207–13.CrossRefGoogle Scholar
  21. 21.
    Papiashvili M, Deviri E, Bar I, Sasson L. Lobectomy for non-small cell lung cancer after coronary bypass grafting surgery. Isr Med Assoc J. 2015;17:430–2.PubMedGoogle Scholar
  22. 22.
    Kunes P, Lonsky V, Mandak J, et al. The long pentraxin 3 in cardiac surgery: distinct responses in “on-pump” and “off-pump” patients. Scand Cardiovasc J. 2007;41:171–9.CrossRefGoogle Scholar
  23. 23.
    Markewitz A, Lante W, Franke A, Marohl K, Kuhlmann WD, Weinhold C. Alterations of cell-mediated immunity following cardiac operations: clinical implications and open questions. Shock. 2001;16(Suppl1):S10–5.CrossRefGoogle Scholar
  24. 24.
    Sablotski A, Dehne M, Welters I, et al. Alterations of the cytokine network in patients undergoing cardiopulmonary bypass. Perfusion. 1997;12:393–403.CrossRefGoogle Scholar
  25. 25.
    Van Der Heiden K, Cuhlmann S, Luong LA, Zakkar M, Evans PC. Role of nuclear factor kappa B in cardiovascular health and disease. Clin Sci. 2010;118:593–605.CrossRefGoogle Scholar
  26. 26.
    Tajima K, Yamamoto E, Kawazoe K, et al. Cardiopulmonary bypass and cellular immunity-changes in lymphocyte subsets and natural killer-cell-activity. Ann Thorac Surg. 1993;55:625–30.CrossRefGoogle Scholar
  27. 27.
    Makino T, Kawada K, Masuhara H, Hat Y, Otsuka H, Koezuka S, Tochiga N, Shibuya K, Watanabe Y, Iyoda A. One-stage operation for thoracic aortic arch aneurysm and left lung carcinoma: a case report. J Cardiothorac Surg. 2016;11:51–3.CrossRefGoogle Scholar
  28. 28.
    Dyszkiewicz W, Jemielity MM, Piwkowski CT, et al. Simultaneous lung resection for cancer and myocardial revascularization without cardiopulmonary bypass (off-pump coronary artery bypass grafting). Ann Thorac Surg. 2004;77:1023–7.CrossRefGoogle Scholar
  29. 29.
    Dyszkiewicz W, Jemielity M, Piwkowski C, et al. The early and late results of combined off-pump coronary artery bypass grafting and pulmonary resection in patients with concomitant lung cancer and unstable coronary heart disease. Eur J Cardiothorac Surg. 2008;34:531–5.CrossRefGoogle Scholar
  30. 30.
    Tourmousoglou C, Apostolakis E, Dougenis D. Simultaneous occurrence of coronary artery disease and lung cancer: what is the best surgical treatment strategy? Interact Cardiovasc Thorac Surg. 2014;19:673–81.CrossRefGoogle Scholar
  31. 31.
    Nguyen P. Editorial. Towards lung preservation in curative surgical treatment of early stage non-small cell lung cancer. Respirology. 2018;23:648–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Rehabilitation Sciences and Physiotherapy Antwerp, Faculty of Medicine and Health SciencesUniversity of AntwerpAntwerpBelgium
  2. 2.Department of Healthcare and WellbeingArtesis-Plantijn University of Applied ScienceAntwerpBelgium

Personalised recommendations